{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:33Z","timestamp":1792518033005,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L248053"],"award-info":[{"award-number":["L248053"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242104"],"award-info":[{"award-number":["7242104"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["UHB11961"],"award-info":[{"award-number":["UHB11961"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["UHB12423"],"award-info":[{"award-number":["UHB12423"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2413400"],"award-info":[{"award-number":["2023YFC2413400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z231100007223006"],"award-info":[{"award-number":["Z231100007223006"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011176","name":"Peking Union Medical College","doi-asserted-by":"publisher","award":["3332025182"],"award-info":[{"award-number":["3332025182"]}],"id":[{"id":"10.13039\/501100011176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473086"],"award-info":[{"award-number":["82473086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403006"],"award-info":[{"award-number":["82403006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473096"],"award-info":[{"award-number":["82473096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2025-I2MXHXX-016"],"award-info":[{"award-number":["2025-I2MXHXX-016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62133006"],"award-info":[{"award-number":["62133006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218558","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:58:32Z","timestamp":1777701512000},"page":"218558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Artificial intelligence: Catalyzing a new era in pancreatic cancer cure"],"prefix":"10.1016","volume":"652","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7008-4876","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menggang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuangyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang dong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218558_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218558_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2026.218558_bib3","unstructured":"Khan N, Raza U, Zaidi SAA, Nuer M, Abudurousuli K, Aikebaier A, et al. Drugging the \u2018Undruggable\u2019 KRAS: Breakthroughs, Challenges, and Opportunities in Pancreatic Cancer n.d.."},{"key":"10.1016\/j.canlet.2026.218558_bib4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218558_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218558_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191939","article-title":"KRAS: the Achilles' heel of pancreas cancer biology","volume":"135","author":"Drizyte-Miller","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218558_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","article-title":"Emerging landscape of KRAS inhibitors in cancer treatment","volume":"44","author":"Riedl","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/jcm15020873","article-title":"KRAS inhibition in pancreatic ductal adenocarcinoma","volume":"15","author":"Pradeep","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib12","series-title":"Value Creat. Pharm. Ind.","first-page":"60","article-title":"A review of the pharmaceutical R&D efficiency: costs, timelines, and probabilities","author":"Schuhmacher","year":"2016"},{"key":"10.1016\/j.canlet.2026.218558_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1208\/s12249-024-02901-y","article-title":"The artificial intelligence-powered new era in pharmaceutical research and development: a review","volume":"25","author":"Suriyaamporn","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.canlet.2026.218558_bib14","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218558_bib15","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","article-title":"A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial","volume":"31","author":"Xu","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","article-title":"A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models","volume":"43","author":"Ren","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218558_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/ph17050551","article-title":"In silico prediction of new inhibitors for Kirsten Rat sarcoma G12D cancer drug target using machine learning-based virtual screening, molecular docking, and molecular dynamic simulation approaches","volume":"17","author":"Ajmal","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.canlet.2026.218558_bib18","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1038\/s41467-025-56818-6","article-title":"AI-driven discovery of synergistic drug combinations against pancreatic cancer","volume":"16","author":"Pourmousa","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218558_bib19","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41587-024-02526-3","article-title":"Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors","volume":"43","author":"Ghazi Vakili","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218558_bib20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218558_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib23","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218558_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218558_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218558_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib30","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib33","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib35","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/cancers14030850","article-title":"Genetic alterations predict long-term survival in ductal adenocarcinoma of the pancreatic head","volume":"14","author":"Safi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218558_bib37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10555-021-09990-2","article-title":"Targeting KRAS in pancreatic cancer: new drugs on the horizon","volume":"40","author":"Bannoura","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2026.218558_bib38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218558_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.canlet.2026.218558_bib40","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.025","article-title":"LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib42","article-title":"Injection combined with AG versus placebo combined with AG therapy in first-line advanced or metastatic pancreatic cancer","year":"2025","journal-title":"ClinicalTrialsGov"},{"key":"10.1016\/j.canlet.2026.218558_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-4394","article-title":"Abstract 4394: GFH375 (VS-7375): an oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models","volume":"85","author":"Pachter","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218558_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.3013","article-title":"A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors","volume":"43","author":"Ai","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS792","article-title":"Phase 1\/2 study of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D\u2013mutated advanced solid tumors, including pancreatic cancer","volume":"44","author":"Murciano-Goroff","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"10.1016\/j.canlet.2026.218558_bib47","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"608O preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib48","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib49","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3390\/ph18121788","article-title":"Broad-spectrum RAS inhibition in pancreatic ductal adenocarcinoma: mechanistic advances and therapeutic promise","volume":"18","author":"Alanazi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.canlet.2026.218558_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib51","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall survival analysis of the phase III CodeBreaK 300 study of sotorasib plus panitumumab versus investigator's choice in chemorefractory KRAS G12C colorectal cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib52","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib53","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"issue":"39","key":"10.1016\/j.canlet.2026.218558_bib54","article-title":"New exploration of KRASG12D inhibitors and the mechanisms of resistance","volume":"14","author":"Li","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218558_bib56","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3390\/ijms20112783","article-title":"A structure-based drug discovery paradigm","volume":"20","author":"Batool","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218558_bib57","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4155\/fmc-2019-0307","article-title":"An overview of drug discovery and development","volume":"12","author":"Berdigaliyev","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.canlet.2026.218558_bib58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fphar.2020.00733","article-title":"Discovering anti-cancer drugs via computational methods","volume":"11","author":"Cui","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218558_bib59","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib61","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.3390\/molecules27175710","article-title":"Computer-aided drug design boosts RAS inhibitor discovery","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2026.218558_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167093","article-title":"Can we AlphaFold our way out of the next pandemic?","volume":"433","author":"Higgins","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218558_bib63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.canlet.2026.218558_bib64","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","article-title":"Deep docking: a deep learning platform for augmentation of structure based drug discovery","volume":"6","author":"Gentile","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.canlet.2026.218558_bib65","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1038\/s41467-024-52061-7","article-title":"An artificial intelligence accelerated virtual screening platform for drug discovery","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218558_bib66","doi-asserted-by":"crossref","first-page":"eads9530","DOI":"10.1126\/science.ads9530","article-title":"Deep contrastive learning enables genome-wide virtual screening","volume":"391","author":"Jia","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218558_bib67","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s43588-024-00737-x","article-title":"Structure-based drug design with equivariant diffusion models","volume":"4","author":"Schneuing","year":"2024","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.canlet.2026.218558_bib68","doi-asserted-by":"crossref","first-page":"nwaf495","DOI":"10.1093\/nsr\/nwaf495","article-title":"Multimodal pre-training models of molecular representation for drug discovery","volume":"13","author":"Wang","year":"2026","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.canlet.2026.218558_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/minf.70027","article-title":"Foundation and multimodal models for drug discovery in molecular informatics: principles, evaluation, and practical guidance","volume":"45","author":"Pastore","year":"2026","journal-title":"Mol. Inf."},{"key":"10.1016\/j.canlet.2026.218558_bib70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/acs.jcim.4c01385","article-title":"DiffInt: a diffusion model for structure-based drug design with explicit hydrogen bond interaction guidance","volume":"65","author":"Sako","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.canlet.2026.218558_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17460441.2026.2636192","article-title":"Deep generative molecular design and its value in modern drug discovery","volume":"21","author":"Ozdemir","year":"2026","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218558_bib72","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1411679111","article-title":"Stromal response to Hedgehog signaling restrains pancreatic cancer progression","volume":"111","author":"Lee","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218558_bib73","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with Hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib74","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib75","doi-asserted-by":"crossref","first-page":"eaau9240","DOI":"10.1126\/scitranslmed.aau9240","article-title":"Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies","volume":"11","author":"Panni","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib76","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-19-4042","article-title":"A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and Gemcitabine\/nab-paclitaxel in pancreatic cancer patients","volume":"26","author":"Zeh","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218558_bib77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF\u2192MEK\u2192ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218558_bib78","article-title":"An in-depth review of AI-powered advancements in cancer drug discovery","volume":"1871","author":"Le","year":"2025","journal-title":"Biochim Biophys. Acta BBA Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2026.218558_bib79","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1038\/s41467-022-34277-7","article-title":"Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218558_bib80","series-title":"Stud. Health Technol. Inform.","doi-asserted-by":"crossref","DOI":"10.3233\/SHTI230158","article-title":"Transfer learning for early prediction of adverse drug reactions: Docetaxel and alopecia in breast cancer as a case study","author":"Dimitsaki","year":"2023"},{"key":"10.1016\/j.canlet.2026.218558_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619865413","article-title":"Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada","volume":"10","author":"Raj","year":"2019","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.canlet.2026.218558_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1609827","article-title":"Artificial intelligence in oncology drug development and management: a precision medicine perspective","volume":"15","author":"Fang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib83","article-title":"Can artificial intelligence improve cancer treatments?","volume":"28","author":"Derbal","year":"2022","journal-title":"Health Inf. J."},{"key":"10.1016\/j.canlet.2026.218558_bib84","doi-asserted-by":"crossref","first-page":"225","DOI":"10.26599\/BDMA.2020.9020008","article-title":"Inference attacks on genomic data based on probabilistic graphical models","volume":"3","author":"He","year":"2020","journal-title":"Big Data Min. Anal."},{"key":"10.1016\/j.canlet.2026.218558_bib85","author":"Stroud"},{"key":"10.1016\/j.canlet.2026.218558_bib86","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/ph18091271","article-title":"Artificial intelligence in small-molecule drug discovery: a critical review of methods, applications, and real-world outcomes","volume":"18","author":"Niazi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.canlet.2026.218558_bib87","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib88","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218558_bib89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41586-022-05082-5","article-title":"Ordered and deterministic cancer genome evolution after p53 loss","volume":"608","author":"Baslan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218558_bib90","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","article-title":"SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer","volume":"15","author":"Blackford","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218558_bib91","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/1471-2458-12-526","article-title":"A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding","volume":"12","author":"Carter","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.canlet.2026.218558_bib92","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(16)30213-8","article-title":"Pancreatic cancer: how can we tackle the lack of progress?","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218558_bib93","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41416-025-03286-w","article-title":"Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer","volume":"134","author":"Yamamoto","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218558_bib95","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/cac2.70056","article-title":"Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: a pooled analysis of two phase I\/II trials","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2026.218558_bib96","volume":"43","author":"Spira","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218558_bib97","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.clinthera.2017.08.015","article-title":"Current standards of chemotherapy for pancreatic cancer","volume":"39","author":"Saung","year":"2017","journal-title":"Clin. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:01:21Z","timestamp":1792515681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526003216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":97,"alternative-id":["S0304383526003216"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218558","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence: Catalyzing a new era in pancreatic cancer cure","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218558"}}